Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Anti-amyloid drugs

Global Marketing, Technology, and Innovation

Jim Lefevere, Director of Global Marketing Services at Roche, discusses the changes in digital marketing strategies, workflow, team dynamics, and required skill sets among Pharma teams brought on by COVID-19....

Impetus Digital

- PMLiVE

Lilly and Foghorn sign oncology deal

Eli Lilly has teamed up with Foghorn Therapeutics to develop drugs that target the chromatin regulatory system using Foghorn's proprietary Gene Traffic Control platform

- PMLiVE

Roche’s lung cancer combination treatment improves long-term survival

Anti-TIGIT therapy tiragolumab plus Tecentriq offers better progression-free survival improvement after 2.5 years than Tecentriq alone

- PMLiVE

Roche’s Actemra approved for severe COVID-19 in Europe

The monoclonal antibody previously used to treat inflammatory conditions such as rheumatoid arthritis is already being used in the US and Australia

- PMLiVE

Lilly’s combination antibody expanded to children under 12

The FDA has expanded the emergency use for bamlanivimab with etesevimab for the treatment of and post-exposure prophylaxis against COVID-19 in high-risk children aged under 12

- PMLiVE

Roche acquires test maker TIB Molbiol

The Swiss biopharmaceutical group has acquired the Berlin-based diagnostics biotech after two decades of collaboration, expanding its PCR test portfolio

- PMLiVE

Roche to present new data for its drug Polivy at the American Society of Hematology’s annual meeting

The company will present 90 abstracts from across a wide range of haematologic diseases, including results from three pivotal studies in lymphoma and haemophilia

- PMLiVE

UK’s NICE recommends Roche’s Evrysdi

The first oral therapy for the leading genetic cause of death among babies and young children will be available to 1,500 people in England after Roche signed a price-cutting deal

- PMLiVE

Roche and Novartis part ways with share purchase

Novartis is to sell its one-third stake in Roche for more than $20bn, paving the way for potential acquisitions

- PMLiVE

Eli Lilly focuses on 2022 launches as revenues climb by 18%

Revenues in the third quarter of 2021 were driven by volume growth in new medicines, but earnings per share were a fraction below analysts’ predictions

- PMLiVE

New data shows Roche’s Enspryng significantly reduces neuromyelitis optica spectrum disorder relapses

Enspryng is the first and only NMOSD treatment administered subcutaneously every four weeks

- PMLiVE

FDA approves Eli Lilly’s Verzenio in high risk early breast cancer

Verzenio is the first addition to adjuvant endocrine therapy approved by the FDA in nearly two decades for the treatment of HR+ HER2- early breast cancer

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links